PitchBook, the premiere data provider for the private and public equity markets, today announced the winners of the 2024 PitchBook Lending League Table Awards. These rankings, part of PitchBook’s ...

InflaRx (NASDAQ:IFRX – Free Report) had its target price hoisted by Guggenheim from $7.00 to $10.00 in a report published on Wednesday morning, Ratings reports. The brokerage currently has a buy ...

Allowing people with state-issued concealed carry licenses or permits to conceal a handgun in any other state, a bill ...

HC Wainwright reissued their buy rating on shares of InflaRx (NASDAQ:IFRX – Free Report) in a report issued on Friday morning ...

Received European Commission approval for GOHIBIC® (vilobelimab) for the treatment of SARS-CoV-2-induced acute respiratory distress syndrome ...

When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. Siri might have been the original voice assistant but Amazon’s Alexa was the first to break free ...

Vilobelimab is a first-in-class monoclonal anti-human complement factor C5a antibody, which targets the biological activity of C5a and demonstrates high selectivity towards its target in human blood.

About InflaRx N.V.: InflaRx (Nasdaq: IFRX) is a biopharmaceutical company pioneering anti-inflammatory therapeutics by applying its proprietary anti-C5a and anti-C5aR technologies to discover ...